Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
peresolimab
- Development stage
- Phase 2
- Lead developer
- Eli Lilly
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
Peresolimab is an investigational humanized immunoglobulin G1 (IgG1) monoclonal antibody that acts as an agonist of programmed cell death protein 1 (PD-1), a checkpoint inhibitory receptor. By stimulating PD-1, peresolimab may induce physiological immune inhibitory pathways to restore immune homeostasis. It is being developed primarily for the treatment of autoimmune diseases, with rheumatoid arthritis as its lead indication. Clinical trials have shown that peresolimab can reduce disease activity in patients with moderate-to-severe rheumatoid arthritis who have had insufficient response to conventional therapies, including biologics and DMARDs. The drug has demonstrated a safety profile comparable to placebo in clinical studies[2][4][5][6].
- Other names
- peresolimabLY3462817LY-3462817LY 3462817
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on peresolimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on peresolimab.